Abstract Coronavirus disease 2019 (COVID-19) is caused by a new member of the
Coronaviridae family known as severe acute respiratory syndrome coronavirus 2 (SARS …

Background The COVID-19 pandemic continues to cause morbidity and mortality worldwide.
Most approved COVID-19 vaccines generate a neutralizing antibody response that primarily …

Despite the robust immunogenicity of SARS-CoV-2 mRNA vaccines, emerging data have
revealed enhanced neutralizing antibody and T cell cross-reactivity among individuals that …

SARS-CoV-2 is the etiological agent of the COVID-19 pandemic. Antibody-based
therapeutics targeting the spike protein, specifically the S1 subunit or the receptor binding …

Using the regioselective cyanobenzothiazole condensation reaction with an N-terminal
cysteine and the chloroacetamide reaction with an internal cysteine, a phage-displayed …

Objectives: This study aimed to determine the safety and immunogenicity of a combined
intramuscular/intranasal recombinant spike protein COVID-19 vaccine (RCP). Methods: We …

The COVID-19 pandemic began at the end of 2019 in Wuhan, China, and has spread
throughout the world. Vaccination is still the most effective method of prevention of …

The COVID-19 pandemic, caused by the SARS-CoV-2 virus, has had and continues to have
a significant impact on global public health. One of the characteristics of SARS-CoV-2 is a …

The potential of immune-evasive mutation accumulation in the SARS-CoV-2 virus has led to
its rapid spread, causing over 600 million confirmed cases and more than 6.5 million …

Neutralizing antibodies (NAbs) can prevent and treat infections caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). However, continuously emerging …